{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:31:38Z","timestamp":1793881898471,"version":"4.7.0"},"reference-count":53,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Hereditary angioedema (HAE) is a rare, autosomal dominant, life\u2010threatening disease characterized by recurrent attacks of swelling of the face, upper airway, gastrointestinal tract, limbs, and\/or genitalia. Genetic mutations of the\n                    <jats:italic>SERPING1<\/jats:italic>\n                    gene encoding the C1\u2010inhibitor (C1\u2010INH) plasma protein are associated with HAE\u2010C1INH. HAE is also observed in patients with normal C1\u2010INH (HAE\u2010nC1INH). Icatibant is a selective bradykinin B2 receptor antagonist for treatment of acute attacks of HAE. Here we report safety and effectiveness data from a post\u2010marketing, open\u2010label, multicenter observational study of icatibant conducted in Japan (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    ID: NCT04057131). Patients with HAE in Japan who initiated icatibant between November 2018 and June 2020 were enrolled; surveillance was completed in April 2023. In the Safety Analysis Set (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009155), most patients were women (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009116, 74.84%) and HAE types included HAE\u2010C1INH\u2010Type 1 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200983, 53.55%), HAE\u2010C1INH\u2010Type 2 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20099, 5.81%), unclassified HAE\u2010C1INH (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200916, 10.32%), and HAE\u2010nC1INH (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200922, 14.19%). Overall, 19 patients (12.26%) experienced adverse drug reactions (ADRs), most of which were mild in severity (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918, 11.61%). The most common ADRs were general disorders and administration site conditions (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918, 11.61%). No serious ADRs or ADRs of special interest other than hypersensitivity and injection site reaction were reported. In the Effectiveness Analysis Set (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009100), 97 patients (97.00%) received 30\u2009mg of icatibant. Among 417 HAE attacks, 234 were treated with icatibant alone and 48 with icatibant plus other. Among attacks treated with icatibant alone, median (interquartile range) time to first symptom relief was 60.0 (30.0\u2013270.0) min, and median time to complete resolution of symptoms was 710.0 (148.5\u20131440.0) min. In conclusion, in this study of the real\u2010world use of icatibant, no new safety concerns were reported. Icatibant was effective in providing early symptom relief for HAE attacks across a broad spectrum of patients, including patients with HAE\u2010nC1INH, who were not included in previous clinical trials.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.70447","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:28:02Z","timestamp":1787380082000},"page":"1599-1614","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema (\n                    <scp>HAE<\/scp>\n                    ): Post\u2010Marketing Surveillance in Japan"],"prefix":"10.1111","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8847-9869","authenticated-orcid":false,"given":"Kumiko","family":"Hosono","sequence":"first","affiliation":[{"name":"Japan Medical Office Takeda Pharmaceutical Company Limited  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9680-7838","authenticated-orcid":false,"given":"Miyako","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Japan Medical Office Takeda Pharmaceutical Company Limited  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0803977"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2013.07.002"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.05.055"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.916275"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/aci.0000000000000082"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2013.34.3685"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2013.05.028"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2014.35.3783"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.20.2417"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102133.2009.09366.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001050050710"},{"key":"e_1_2_9_13_1","first-page":"327","article-title":"Type I Hereditary Angioedema in Taiwan\u2014Clinical, Biological Features and Genetic Study","volume":"29","author":"Lei W. T.","year":"2011","journal-title":"Asian Pacific Journal of Allergy and Immunology"},{"key":"e_1_2_9_14_1","first-page":"s103","article-title":"Overview of Epidemiology, Pathophysiology, and Disease Progression in Hereditary Angioedema","volume":"19","author":"Lumry W. R.","year":"2013","journal-title":"American Journal of Managed Care"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1081\u20101206(10)61121\u20100"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0171\u20102985(98)80040\u20105"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016\u2010025\u201009027\u20104"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2023.04.004"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100627"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100223"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.05.017"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2022.01130"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8624\u201016"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15034"},{"key":"e_1_2_9_25_1","first-page":"26","article-title":"National Prevalence Survey of Hereditary Angioedema in Japan","volume":"60","author":"Iwamoto K.","year":"2011","journal-title":"Arerug\u012b"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.09.008"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223\u2010025\u201000999\u20108"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.70207"},{"key":"e_1_2_9_29_1","volume-title":"Firazyr (Icatibant Injection)","year":"2025"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906393"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12358"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12244"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2011.08.015"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000441060"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.08.012"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.07.008"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1400526"},{"key":"e_1_2_9_38_1","unstructured":"\u201cList of Approved Drugs April 2004 to June 2025 \u201d Pharmaceuticals and Medical Devices Agency (Japan) (2025) https:\/\/www.pmda.go.jp\/english\/review\u2010services\/reviews\/approved\u2010information\/drugs\/0002.html."},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000430864"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2025.101100"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2015.06.006"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2024.12.012"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.24176"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.08.026"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100446"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.137"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102249.2012.04574.x"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.2147\/ijwh.S46460"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2177269"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875\u2010018\u20100553\u20104"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jog.13003"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.2500\/ar.2017.8.0210"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882\u2010022\u201001040\u20103"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.1111"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70447","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.70447","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:13:08Z","timestamp":1793880788000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.70447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/1346-8138.70447"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.70447","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2026-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}